Inhibiting Skp2 E3 ligase suppresses bleomycin-induced pulmonary fibrosis

Masashi Mikamo, Kyoko Kitagawa, Satoshi Sakai, Chiharu Uchida, Tatsuya Ohhata, Koji Nishimoto, Hiroyuki Niida, Sayuri Suzuki, Keiichi I. Nakayama, Naoki Inui, Takafumi Suda, Masatoshi Kitagawa

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抄録

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis and no curative therapies. SCF-Skp2 E3 ligase is a target for cancer therapy, but there have been no reports about Skp2 as a target for IPF. Here we demonstrate that Skp2 is a promising therapeutic target for IPF. We examined whether disrupting Skp2 suppressed pulmonary fibrosis in a bleomycin (BLM)-induced mouse model and found that pulmonary fibrosis was significantly suppressed in Skp2-deficient mice compared with controls. The pulmonary accumulation of fibrotic markers such as collagen type 1 and fibronectin in BLM-infused mice was decreased in Skp2-deficient mice. Moreover, the number of bronchoalveolar lavage fluid cells accompanied with pulmonary fibrosis was significantly diminished. Levels of the Skp2 target p27 were significantly decreased by BLM-administration in wild-type mice, but recovered in Skp2 −/− mice. In vimentin-positive mesenchymal fibroblasts, the decrease of p27-positive cells and increase of Ki67-positive cells by BLM-administration was suppressed by Skp2-deficency. As these results suggested that inhibiting Skp2 might be effective for BLM-induced pulmonary fibrosis, we next performed a treatment experiment using the Skp2 inhibitor SZL-P1-41. As expected, BLM-induced pulmonary fibrosis was significantly inhibited by SZL-P1-41. Moreover, p27 levels were increased by the SZL-P1-41 treatment, suggesting p27 may be an important Skp2 target for BLM-induced pulmonary fibrosis. Our study suggests that Skp2 is a potential molecular target for human pulmonary fibrosis including IPF.

元の言語英語
記事番号474
ジャーナルInternational journal of molecular sciences
19
発行部数2
DOI
出版物ステータス出版済み - 2 6 2018

Fingerprint

fibrosis
Ubiquitin-Protein Ligases
Pulmonary Fibrosis
Bleomycin
Cells
Idiopathic Pulmonary Fibrosis
Fibroblasts
Collagen
mice
Fluids
Vimentin
Collagen Type I
Fibronectins
Experiments
Therapeutics
Bronchoalveolar Lavage Fluid
therapy
disrupting
prognosis
fibroblasts

All Science Journal Classification (ASJC) codes

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

これを引用

Mikamo, M., Kitagawa, K., Sakai, S., Uchida, C., Ohhata, T., Nishimoto, K., ... Kitagawa, M. (2018). Inhibiting Skp2 E3 ligase suppresses bleomycin-induced pulmonary fibrosis. International journal of molecular sciences, 19(2), [474]. https://doi.org/10.3390/ijms19020474

Inhibiting Skp2 E3 ligase suppresses bleomycin-induced pulmonary fibrosis. / Mikamo, Masashi; Kitagawa, Kyoko; Sakai, Satoshi; Uchida, Chiharu; Ohhata, Tatsuya; Nishimoto, Koji; Niida, Hiroyuki; Suzuki, Sayuri; Nakayama, Keiichi I.; Inui, Naoki; Suda, Takafumi; Kitagawa, Masatoshi.

:: International journal of molecular sciences, 巻 19, 番号 2, 474, 06.02.2018.

研究成果: ジャーナルへの寄稿記事

Mikamo, M, Kitagawa, K, Sakai, S, Uchida, C, Ohhata, T, Nishimoto, K, Niida, H, Suzuki, S, Nakayama, KI, Inui, N, Suda, T & Kitagawa, M 2018, 'Inhibiting Skp2 E3 ligase suppresses bleomycin-induced pulmonary fibrosis', International journal of molecular sciences, 巻. 19, 番号 2, 474. https://doi.org/10.3390/ijms19020474
Mikamo, Masashi ; Kitagawa, Kyoko ; Sakai, Satoshi ; Uchida, Chiharu ; Ohhata, Tatsuya ; Nishimoto, Koji ; Niida, Hiroyuki ; Suzuki, Sayuri ; Nakayama, Keiichi I. ; Inui, Naoki ; Suda, Takafumi ; Kitagawa, Masatoshi. / Inhibiting Skp2 E3 ligase suppresses bleomycin-induced pulmonary fibrosis. :: International journal of molecular sciences. 2018 ; 巻 19, 番号 2.
@article{68c19cabdccb4f39b20acad50c51e2a7,
title = "Inhibiting Skp2 E3 ligase suppresses bleomycin-induced pulmonary fibrosis",
abstract = "Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis and no curative therapies. SCF-Skp2 E3 ligase is a target for cancer therapy, but there have been no reports about Skp2 as a target for IPF. Here we demonstrate that Skp2 is a promising therapeutic target for IPF. We examined whether disrupting Skp2 suppressed pulmonary fibrosis in a bleomycin (BLM)-induced mouse model and found that pulmonary fibrosis was significantly suppressed in Skp2-deficient mice compared with controls. The pulmonary accumulation of fibrotic markers such as collagen type 1 and fibronectin in BLM-infused mice was decreased in Skp2-deficient mice. Moreover, the number of bronchoalveolar lavage fluid cells accompanied with pulmonary fibrosis was significantly diminished. Levels of the Skp2 target p27 were significantly decreased by BLM-administration in wild-type mice, but recovered in Skp2 −/− mice. In vimentin-positive mesenchymal fibroblasts, the decrease of p27-positive cells and increase of Ki67-positive cells by BLM-administration was suppressed by Skp2-deficency. As these results suggested that inhibiting Skp2 might be effective for BLM-induced pulmonary fibrosis, we next performed a treatment experiment using the Skp2 inhibitor SZL-P1-41. As expected, BLM-induced pulmonary fibrosis was significantly inhibited by SZL-P1-41. Moreover, p27 levels were increased by the SZL-P1-41 treatment, suggesting p27 may be an important Skp2 target for BLM-induced pulmonary fibrosis. Our study suggests that Skp2 is a potential molecular target for human pulmonary fibrosis including IPF.",
author = "Masashi Mikamo and Kyoko Kitagawa and Satoshi Sakai and Chiharu Uchida and Tatsuya Ohhata and Koji Nishimoto and Hiroyuki Niida and Sayuri Suzuki and Nakayama, {Keiichi I.} and Naoki Inui and Takafumi Suda and Masatoshi Kitagawa",
year = "2018",
month = "2",
day = "6",
doi = "10.3390/ijms19020474",
language = "English",
volume = "19",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Inhibiting Skp2 E3 ligase suppresses bleomycin-induced pulmonary fibrosis

AU - Mikamo, Masashi

AU - Kitagawa, Kyoko

AU - Sakai, Satoshi

AU - Uchida, Chiharu

AU - Ohhata, Tatsuya

AU - Nishimoto, Koji

AU - Niida, Hiroyuki

AU - Suzuki, Sayuri

AU - Nakayama, Keiichi I.

AU - Inui, Naoki

AU - Suda, Takafumi

AU - Kitagawa, Masatoshi

PY - 2018/2/6

Y1 - 2018/2/6

N2 - Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis and no curative therapies. SCF-Skp2 E3 ligase is a target for cancer therapy, but there have been no reports about Skp2 as a target for IPF. Here we demonstrate that Skp2 is a promising therapeutic target for IPF. We examined whether disrupting Skp2 suppressed pulmonary fibrosis in a bleomycin (BLM)-induced mouse model and found that pulmonary fibrosis was significantly suppressed in Skp2-deficient mice compared with controls. The pulmonary accumulation of fibrotic markers such as collagen type 1 and fibronectin in BLM-infused mice was decreased in Skp2-deficient mice. Moreover, the number of bronchoalveolar lavage fluid cells accompanied with pulmonary fibrosis was significantly diminished. Levels of the Skp2 target p27 were significantly decreased by BLM-administration in wild-type mice, but recovered in Skp2 −/− mice. In vimentin-positive mesenchymal fibroblasts, the decrease of p27-positive cells and increase of Ki67-positive cells by BLM-administration was suppressed by Skp2-deficency. As these results suggested that inhibiting Skp2 might be effective for BLM-induced pulmonary fibrosis, we next performed a treatment experiment using the Skp2 inhibitor SZL-P1-41. As expected, BLM-induced pulmonary fibrosis was significantly inhibited by SZL-P1-41. Moreover, p27 levels were increased by the SZL-P1-41 treatment, suggesting p27 may be an important Skp2 target for BLM-induced pulmonary fibrosis. Our study suggests that Skp2 is a potential molecular target for human pulmonary fibrosis including IPF.

AB - Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor prognosis and no curative therapies. SCF-Skp2 E3 ligase is a target for cancer therapy, but there have been no reports about Skp2 as a target for IPF. Here we demonstrate that Skp2 is a promising therapeutic target for IPF. We examined whether disrupting Skp2 suppressed pulmonary fibrosis in a bleomycin (BLM)-induced mouse model and found that pulmonary fibrosis was significantly suppressed in Skp2-deficient mice compared with controls. The pulmonary accumulation of fibrotic markers such as collagen type 1 and fibronectin in BLM-infused mice was decreased in Skp2-deficient mice. Moreover, the number of bronchoalveolar lavage fluid cells accompanied with pulmonary fibrosis was significantly diminished. Levels of the Skp2 target p27 were significantly decreased by BLM-administration in wild-type mice, but recovered in Skp2 −/− mice. In vimentin-positive mesenchymal fibroblasts, the decrease of p27-positive cells and increase of Ki67-positive cells by BLM-administration was suppressed by Skp2-deficency. As these results suggested that inhibiting Skp2 might be effective for BLM-induced pulmonary fibrosis, we next performed a treatment experiment using the Skp2 inhibitor SZL-P1-41. As expected, BLM-induced pulmonary fibrosis was significantly inhibited by SZL-P1-41. Moreover, p27 levels were increased by the SZL-P1-41 treatment, suggesting p27 may be an important Skp2 target for BLM-induced pulmonary fibrosis. Our study suggests that Skp2 is a potential molecular target for human pulmonary fibrosis including IPF.

UR - http://www.scopus.com/inward/record.url?scp=85041539839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041539839&partnerID=8YFLogxK

U2 - 10.3390/ijms19020474

DO - 10.3390/ijms19020474

M3 - Article

C2 - 29415439

AN - SCOPUS:85041539839

VL - 19

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 2

M1 - 474

ER -